30-day FRN

40708

Federal Register / Vol. 81, No. 120 / Wednesday, June 22, 2016 / Notices

Neuroscience & Basic Behavioral
Science, National Institute of Mental
Health, National Institutes of Health,
6001 Executive Blvd., MSC9645,
Bethesda, MD 20892–9645,
biospecimens2@mail.nih.gov, 301–443–
3107.
Sample
collection, processing, and storage
procedures have the potential to affect
assay results for basic research,
biomarker discovery, biomarker
validation, and development of
validated assays. Variability in these
procedures may also decrease data rigor,
thereby increasing the likelihood of
irreproducible data, incorrect
conclusions, and delays in advancing
scientific knowledge.
Recent genetic studies have provided
compelling evidence in support of the
long-held hypothesis that alterations in
immune function are associated with
the pathophysiology of mental illnesses.
Abnormal blood levels of cytokines
have been reported in schizophrenia,
bipolar disorder and major depressive
illness. However, our understanding of
the role of immune system markers in
mental illnesses has not advanced due
in part to between-study heterogeneity
in immune assay methodology,
diagnosis criteria, severity of disease,
number and age of samples, and other
potential confounds (e.g., medication,
comorbidities) (Goldsmith, DR et al.,
Mol. Psychiatry, 23 February 2016;
doi:10.1038/mp.2016.3).
The creation of an agreed upon,
standard panel of pro- and antiinflammatory markers, along with
adoption of a standard approach for
sample collection and handling, would
be a valuable resource for evaluation of
inflammatory processes in mental
illnesses.
This request for information (RFI)
seeks information from the community
about the availability, quality, and
degree of clinical characterization of
plasma and CSF samples that could
potentially be used for assessing the
technical performance of a panel of
inflammatory markers and the utility of
the panel for sub-typing individuals and
tracking disease progression in
individuals with mental illness.
The NIMH seeks information on the
following:
1. Source and number of samples
available for each disorder and for
healthy controls. Include the number of
plasma samples and the number of CSF
samples available, and whether both
plasma and CSF samples are available
from the same individuals.
2. SOPs used for sample collection
and storage

mstockstill on DSK3G9T082PROD with NOTICES

SUPPLEMENTARY INFORMATION:

VerDate Sep<11>2014

20:02 Jun 21, 2016

Jkt 238001

3. Available clinical data: diagnosis,
age of onset and duration of illness,
demographics, medications, comorbidities
4. Consent for sharing of samples
5. Contact information for the
individual responsible for the samples
Respondents are encouraged to
include any other information that they
deem relevant to the purpose of this
RFI.
The NIH will use the information
submitted in response to this RFI at its
discretion and will not provide
comments to any responder’s
submission. However, responses to the
RFI may be reflected in future funding
opportunity announcements. The
information provided will be analyzed
and may be aggregated in reports.
Respondents are advised that the
Government is under no obligation to
acknowledge receipt of the information
received or provide feedback to
respondents with respect to any
information submitted. No proprietary,
classified, confidential, or sensitive
information should be included in your
response. The Government reserves the
right to use any non-proprietary
technical information in any resultant
solicitation(s).
Dated: June 16, 2016.
Shelli Avenevoli,
Acting Deputy Director, National Institute of
Mental Health.
[FR Doc. 2016–14740 Filed 6–21–16; 8:45 am]
BILLING CODE 4140–01–P

Date: July 14, 2016.
Time: 10:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852, (Telephone
Conference Call).
Contact Person: Hiromi Ono, Ph.D.,
Scientific Review Officer, Office of
Extramural Affairs, National Institute on
Drug Abuse, National Institutes of Health,
DHHS, 6001 Executive Boulevard, Room
4238, MSC 9550, Bethesda, MD 20892, 301–
402–6020, hiromi.ono@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel Summer
Research Education Experience Programs
(R25).
Date: July 19, 2016.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852, (Telephone
Conference Call).
Contact Person: Susan O. McGuire, Ph.D.,
Scientific Review Officer, Office of
Extramural Affairs, National Institute on
Drug Abuse, National Institutes of Health,
DHHS, 6001 Executive Blvd., Room 4245,
Rockville, MD 20852, 301–435–1426,
mcguireso@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos.: 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
Dated: June 17, 2016.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–14777 Filed 6–21–16; 8:45 am]

DEPARTMENT OF HEALTH AND
HUMAN SERVICES

BILLING CODE 4140–01–P

National Institutes of Health

DEPARTMENT OF HEALTH AND
HUMAN SERVICES

National Institute on Drug Abuse;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel
Mechanism for Time-Sensitive Drug Abuse
Research (R21).

PO 00000

Frm 00056

Fmt 4703

Sfmt 4703

National Institutes of Health
Submission for OMB Review; 30-Day
Comment Request; NLM PEOPLE
LOCATOR® System
Under the provisions of
Section 3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the National
Institutes of Health (NIH) has submitted
to the Office of Management and Budget
(OMB) a request for review and
approval of the information collection
listed below. This proposed information
collection was previously published in
the Federal Register on April 15, 2016,
page 22289 and allowed 60 days for
public comment. There were no
comments received. The purpose of this
notice is to allow an additional 30 days
for public comment. The National
Library of Medicine (NLM), National
Institutes of Health, may not conduct or

SUMMARY:

E:\FR\FM\22JNN1.SGM

22JNN1

40709

Federal Register / Vol. 81, No. 120 / Wednesday, June 22, 2016 / Notices
sponsor, and the respondent is not
required to respond to, an information
collection that has been extended,
revised, or implemented on or after
October 1, 1995, unless it displays a
currently valid OMB control number.
Direct Comments to OMB: Written
comments and/or suggestions regarding
the item(s) contained in this notice,
especially regarding the estimated
public burden and associated response
time, should be directed to the: Office
of Management and Budget, Office of
Regulatory Affairs, OIRA_submission@
omb.eop.gov or by fax to 202–395–6974,
Attention: NIH Desk Officer.
Comment Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 30 days of the date of
this publication.
FOR FURTHER INFORMATION CONTACT: To
obtain a copy of the data collection
plans and instruments or request more
information on the proposed project
contact: David Sharlip, Office of
Administrative and Management
Analysis Services, National Library of
Medicine, Building 38A, Room B2N12,
8600 Rockville Pike, Bethesda, MD
20894, or call non-toll-free number (301)
402–9680, or Email your request,
including your address to: sharlipd@
mail.nih.gov. Formal requests for
additional plans and instruments must
be requested in writing.
Proposed Collection: NLM People
Locator System, 0925–0612, Expiration

Date 07/31/2016, EXTENSION, National
Library of Medicine (NLM), National
Institutes of Health (NIH).
Need and Use of Information
Collection: This collection of data is
intended to assist in the reunification of
family members and friends who are
separated during a disaster. Experience
in operational drills and during realworld disasters such as the January 2010
earthquakes in Haiti demonstrates that
family members and loved ones are
often separated during disasters and
have significant difficulty determining
each other’s safety, condition, and
location. Reunification can not only
improve their emotional well-being
during the recovery period, but also
improve the chances that injured
victims will be cared for once they are
released from urgent medical care.
Family and friends are also a valuable
source of medical information that may
be important to the care of injured
victims (e.g., by providing family or
personal medical history, information
about allergies). The National Library of
Medicine (NLM) aims to assist Federal,
State and Local agencies in disaster
relief efforts and to serve its mission of
supporting national efforts to the
response to disasters via the PEOPLE
LOCATOR® system and related mobile
app (ReUniteTM) developed as part of
the intramural Lost Person Finder (LPF)
R&D project. The information collection
would support efforts to reunite family
and friends who are separated during a

disaster. Information about missing
(‘‘lost’’) people would be collected from
family members or loved ones who are
searching for them. Information about
recovered (‘‘found’’) people could be
provided by medical personnel,
volunteers and other relief workers
assisting in the disaster recovery effort.
Information collected about missing and
recovered persons would vary including
any one of the following and possibly
all: A photograph, name (if available for
a found person), age group (child, adult)
and/or range, gender, status (alive and
well, injured, deceased, unknown), and
location. The information collection
would be voluntary. It would be
activated only during times of declared
emergencies, training and
demonstration support activities, and
would operate in declared emergencies
until relief efforts have ceased in
response to a particular disaster. This
data collection is authorized pursuant to
sections 301, 307, 465 and 478A of the
Public Health Service Act [42 U.S.C.
241, 242, 286 and 286d]. NLM has in its
mission the development and
coordination of communication
technology to improve the delivery of
health services.
OMB approval is requested for 3
years. There are no costs to respondents
other than their time. The total
estimated annualized burden hours are
7,500.

ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents

Types of respondent

Average time
per response
(in hours)

Total annual
burden hours

Emergency Care First-Responders, Physicians, Other Health Care Providers ............................................................................................................
Family members seeking a missing person ....................................................

500
50,000

100
2

3/60
3/60

2,500
5,000

Total ..........................................................................................................

50,500

150,000

........................

7,500

Dated: June 16, 2016.
David Sharlip,
Project Clearance Liaison, NLM, NIH.
[FR Doc. 2016–14825 Filed 6–21–16; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
mstockstill on DSK3G9T082PROD with NOTICES

Number of
responses per
respondent

National Institutes of Health
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as

VerDate Sep<11>2014

20:02 Jun 21, 2016

Jkt 238001

amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special

PO 00000

Frm 00057

Fmt 4703

Sfmt 4703

Emphasis Panel; Epilepsy Therapy Screening
Program Review.
Date: June 23, 2016.
Time: 11:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852, (Telephone
Conference Call).
Contact Person: Tiziana Paola Cogliati,
Ph.D., Scientific Review Administrator,
Scientific Review Branch, NINDS/NIH/
DHHS, Neuroscience Center, 6001 Executive
Blvd., Suite 3204, MSC 9529, Bethesda, MD
20892–9529, 301–496–8223,
Tiziana.cogliati@mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing

E:\FR\FM\22JNN1.SGM

22JNN1